HK1033876A1 - Use of nmda antagonists for treatment of irritablebowel syndrome. - Google Patents

Use of nmda antagonists for treatment of irritablebowel syndrome.

Info

Publication number
HK1033876A1
HK1033876A1 HK01104450A HK01104450A HK1033876A1 HK 1033876 A1 HK1033876 A1 HK 1033876A1 HK 01104450 A HK01104450 A HK 01104450A HK 01104450 A HK01104450 A HK 01104450A HK 1033876 A1 HK1033876 A1 HK 1033876A1
Authority
HK
Hong Kong
Prior art keywords
treatment
nmda antagonists
irritablebowel
syndrome
irritablebowel syndrome
Prior art date
Application number
HK01104450A
Other languages
English (en)
Inventor
Aziz Asghar
Jose Luis Cabero
Andrew Dray
Anne King
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1033876A1 publication Critical patent/HK1033876A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK01104450A 1998-04-28 2001-06-27 Use of nmda antagonists for treatment of irritablebowel syndrome. HK1033876A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
HK1033876A1 true HK1033876A1 (en) 2001-09-28

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01104450A HK1033876A1 (en) 1998-04-28 2001-06-27 Use of nmda antagonists for treatment of irritablebowel syndrome.

Country Status (21)

Country Link
EP (1) EP1073431B1 (xx)
JP (1) JP2002512956A (xx)
KR (1) KR100569777B1 (xx)
CN (1) CN1200702C (xx)
AR (1) AR016212A1 (xx)
AT (1) ATE270545T1 (xx)
AU (1) AU760783B2 (xx)
BR (1) BR9909971A (xx)
CA (1) CA2329328A1 (xx)
DE (1) DE69918541T2 (xx)
DK (1) DK1073431T3 (xx)
ES (1) ES2221753T3 (xx)
HK (1) HK1033876A1 (xx)
IL (1) IL138919A0 (xx)
MY (1) MY121063A (xx)
NO (1) NO20005386L (xx)
NZ (1) NZ507436A (xx)
PT (1) PT1073431E (xx)
SA (1) SA99200482B1 (xx)
TW (1) TW570793B (xx)
WO (1) WO1999055323A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064202A2 (en) * 2000-03-01 2001-09-07 Euro-Celtique S.A. Tramadol for the treatment of functional gastrointestinal disorders
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
MXPA05009640A (es) * 2003-03-14 2005-10-26 Agi Therapeutics Ltd Tratamiento de condiciones intestinales con n-2,3,3-tetrametilbiciclo [2.2.1] heptan-3-amina.
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
EP3817746A4 (en) * 2018-07-06 2022-04-06 Algernon Pharmaceuticals Inc. COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND METHODS THEREOF
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
AR016212A1 (es) 2001-06-20
IL138919A0 (en) 2001-11-25
EP1073431B1 (en) 2004-07-07
AU760783B2 (en) 2003-05-22
ES2221753T3 (es) 2005-01-01
TW570793B (en) 2004-01-11
JP2002512956A (ja) 2002-05-08
NO20005386D0 (no) 2000-10-26
CN1307471A (zh) 2001-08-08
WO1999055323A1 (en) 1999-11-04
CN1200702C (zh) 2005-05-11
CA2329328A1 (en) 1999-11-04
KR100569777B1 (ko) 2006-04-11
ATE270545T1 (de) 2004-07-15
EP1073431A1 (en) 2001-02-07
DK1073431T3 (da) 2004-10-04
DE69918541D1 (de) 2004-08-12
BR9909971A (pt) 2000-12-26
PT1073431E (pt) 2004-10-29
DE69918541T2 (de) 2005-08-18
SA99200482B1 (ar) 2006-06-27
NZ507436A (en) 2003-09-26
AU4302499A (en) 1999-11-16
MY121063A (en) 2005-12-30
KR20010043077A (ko) 2001-05-25
NO20005386L (no) 2000-10-26

Similar Documents

Publication Publication Date Title
ZA99454B (en) Novel dosage form.
ZA200107291B (en) Use of xenon for treating neurointoxications.
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
IL146105A0 (en) 5-pyridyl-1, 3-azole compounds, process for producing the same and use thereof
ZA993345B (en) Nefazodone dosage form.
ZA996133B (en) Substituted benzamides.
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
HK1041827A1 (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the dame.
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
MXPA02012791A (es) Compuestos dds y metodo para prepararlo.
ZA9810214B (en) 2-arylbenzo(b)thiophenes useful for the treatment of estrogen deprivation syndrome.
IL142524A0 (en) Drug delivery device, especially for the delivery of androgens
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
HUP9900123A3 (en) 1-isothiazolidinone derivatives of azetidine-2-one, processes for the preparation thereof and use thereof
ZA9711057B (en) Process for the preparation of nmda antagonists.
SI1073431T1 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
ZA996659B (en) Apparatus for cleaning flat surfaces.
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj
ZA200110137B (en) Phenoxypropylamine compounds.
SI1068199T1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
ZA200205839B (en) Methods for the treatment of substance abuse.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080428